Bristol Myers Squibb: the value of immuno-oncology in serving patients
Bristol Myers Squibb (BMS), a leading biopharmaceutical company, held a press conference in Cyprus on June 9, 2026, during which distinguished medical oncologists highlighted the key factors for improving cancer patient care. Particular emphasis was placed on early diagnosis, the multidisciplinary approach and modern treatment options, with immuno-oncology taking centre stage as a transformative force in contemporary cancer care. The event was moderated by Eleni Demetriou, Di
Bristol Myers Squibb recently convened medical oncologists in Cyprus to discuss advancements in cancer care. The discussion highlighted early diagnosis, multidisciplinary teams, and modern treatments, with a strong focus on immuno-oncology's impact. Company representatives emphasized the role of innovative therapies in transforming cancer from terminal to chronic conditions. They also stressed their commitment to research, equitable patient access, and healthcare system sustainability.
Experts underscored the importance of patient-centered decision-making within multidisciplinary teams. Prevention and early detection were identified as crucial for improving survival rates, with Cyprus showing high survival rates for several common cancers compared to EU averages.
The discussion underscores the significant progress and ongoing efforts in cancer treatment, particularly highlighting the transformative potential of immuno-oncology and patient-centric approaches in improving outcomes.
📌 Kaynak
Bu özet Cyprus Mail kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →